• 1
    Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 73744.
  • 2
    Sternlicht MD, Coussens LM, Vu TH, Werb Z. Biology and regulation of the matrix metalloproteinases. In: AppeltK, ed. Matrix metalloproteinase inhibitors in cancer therapy. Totowa, NJ: Humana, 2001. 137.
  • 3
    Nagase H. Substrate specificity of MMPs. In: AppeltK, ed. Matrix metalloproteinase inhibitors in cancer therapy. Totowa, NJ: Humana, 2001. 3966.
  • 4
    Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 126070.
  • 5
    Cocket MI, Murohy G, Birch ML, O'Connell JP, Crabbe T, Millican AT, Hart IR, Dochery AJ. Matrix metalloproteinase and metastatic cancer. Biochem Soc Symp 1998; 63: 295313.
  • 6
    Himelstein BP, Canete-Soler R, Bernhard EJ, Muschel RJ. Induction of fibroblast 92kDa gelatinase/type IV collagenase expression by direct contact with metastatic tumor cells. J Cell Sci 1994; 107 (Part 2): 47786.
  • 7
    Zucker S, Hymowitz M, Conner C, Zarrabi HM, Hurewitz AN, Matrisian L, Boyd D, Nicolson G, Montana S. Measurement of matrix metalloproteinase and tissue inhibitors in blood and tissue: clinical and experimental applications. Ann Acad Sci 1999; 878: 21227.
  • 8
    Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 678.
  • 9
    Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000; 2: 2527.
  • 10
    Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS, Di GH, Liu G, Li FM, Ou ZL, Jie C, Shen ZZ et al. Prognostic value of matrix metalloproteinase (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat 2004; 88: 7585.
  • 11
    Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T. MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma. Breast Cancer Res Treat 1999; 58: 28793.
  • 12
    Hanemaaijer R, Verheijen JH, Maguire TM, Visser H, Toet K, McDermott E, O'Higgins N, Duffy MJ. Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int J Cancer 2000; 86: 2047.
  • 13
    Mook ORF, Frederiks WM, Van Noorden JF. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 2004; 1705: 6989.
  • 14
    Waas ET, Lomme RM, DeGroot J, Wobbes T, Hendriks T. Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br J Cancer 2002; 86: 187683.
  • 15
    Ranuncolo SM, Armanasco E, Cresta C, Joffe EB, Puricelli L. Plasma MMP-9 (92-kDA-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer 2003; 106: 74551.
  • 16
    Verheijen JH, Nieuwenbroek NME, Beekman B. Modified proenzymes as artificial substrates for proteolytic enzymes: colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase. Biochem J 1997; 323: 6039.
  • 17
    Kjeldsen L, Bjerrum OW, Hovgaard D, Johnsen AH, Sehested M, Borregaard N. Human neutrophil gelatinase: a marker for circulating neutrophils. Purification and quantification by enzyme linked immunorsorbent assay. Eur J Haematol 1992; 49: 18090.
  • 18
    Vernooy JH, Lindeman JH, Jacobs JA, Hanemaaijer R, Wouters EF. Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest 2004; 126: 180210.
  • 19
    Somiari SB, Shriver CD, Heckman C, Olsen C, Hu H, Jordan R, Arciero C, Russell S, Garguilo G, Hooke J, Somiari R. Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer. Cancer Lett 2006; 233: 98107.
  • 20
    Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, Harper J, Tamyakopoulos G, Moses MA. Matrix metalloproteinase-2 required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci USA 2000; 97: 38849.
  • 21
    Zucker S, Lysik RM, Zarrabi MH, Moll U. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 1993; 53: 1406.
  • 22
    Sheen-Chen S, Chen H, Eng H, Sheen C, Chen W. Serum levels of matrix metalloproteinase 2 in patients with breast cancer. Cancer Lett 2001; 173: 7982.
  • 23
    Jung K, Lein M, Laube C, Lichtinghan R. Blood specimen collection methods influence the concentration and diagnostic validity of matrix metalloproteinase 9 in blood. Clin Chim Acta 2001; 314: 2414.
  • 24
    Lein M, Nowak L, Jung K, Koenig F, Lichtinghagen R, Schnorr D, Loening SA. Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood. Clin Biochem 1997; 30: 4916.
  • 25
    Somiari SB, Somiari RI, Hooke J, Garguilo G, Mittal V, Hu H, Bronfman L, Bombatch J, Deyarmin B, Heckman C, Russell S, Malicki L et al. Establishment and management of a comprehensive biorepository for integrated high throughput genomics and proteomics research. Trans Integr Biomed Inf Enabling Technol Symp J 2004; 1: 13143. Available at:
  • 26
    Gail MH, Brinton LA, Byar DP, Corle DK, Green BS, Schairer C, Mulvihill JJ. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. Natl Cancer Inst 1989; 81: 187886.
  • 27
    Conover WJ. Practical nonparametric statistics, 3rd edn. New York: Wiley, 1999.
  • 28
    Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics 2005. CA Cancer J Clin 2005; 55: 1030.
  • 29
    Arciero C, Somiari S, Shriver C et al. Functional relationship and gene ontology classification of breast cancer biomarkers. Int J Biol Markers 2003; 18: 24172.
  • 30
    Brown P. Risk assessment: controversies and management of moderate-to-high-risk individuals. Breast J 2005;11 Suppl l ( ): S119.
  • 31
    Euhus DM. Understanding mathematical models for breast cancer risk assessment and counseling. Breast J 2001; 7: 22432.
  • 32
    Euhus DM, Leitch AM, Huth JF, Peters GN. Limitations of the Gail model in the specialized breast cancer risk assessment clinic. Breast J 2002; 8: 237.
  • 33
    Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994; 73: 64351.
  • 34
    Constantine JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS. Validation studies for models projecting the risk of invasion and total breast cancer incidence. J Natl Cancer Inst 1999; 91: 15418.
  • 35
    Spiegelman D, Colditz GA, Hunter D, Hertzmark E. Validation of the Gail et al. model for predicting individual breast cancer risk. J Natl Cancer Inst 1994; 86: 6007.
  • 36
    Tice JA, Miike R, Adduci K, Petrakis NL, King E, Wrensch MR. Nipple aspirate fluid and the Gail model for breast cancer risk assessment in a screening population. Cancer Epidemiol Biomarkers Prev 2005; 14: 3248.
  • 37
    Lewis CM, Cler LR, Bu DW, Zochbauer-Muller S, Milchgrub S, Naftalis EZ, Leitch AM, Minna JD, Euhus DM. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res 2005; 11: 16672.
  • 38
    Dudoit S, Fridlyand J, Speed TP. Comparison of discrimination methods for the classification of tumors using gene expression data. J Am Stat Assoc 2002; 97: 7787.
  • 39
    Ruokolainen H, Paakko P, Turpeenniemi T. Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker. Int J Cancer 2005; 116: 4227.
  • 40
    Souza-Tarala CD, Uzuelli JA, Machado AA, Gerlach RF, Tanus-Santos JE. Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin Biochem 2005; 38: 4104.